Ondansetron Stada (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Stada, is a 5-HT3 receptor antagonist presented as a strength/form for intramuscular, intravenous use. It prevents and treats chemotherapy‑induced, radiotherapy‑induced and postoperative nausea and vomiting in patients receiving these therapies.

GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting associated with several therapeutic contexts.

- Chemotherapy‑induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: reduces nausea and vomiting that occur during or after radiation treatment. - Postoperative nausea and vomiting: helps control nausea and vomiting following surgical procedures.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Diarrhoea: loose stools. - Injection site pain: discomfort at the site of administration.

Serious or Rare Side Effects: - QT interval prolongation: possible cardiac arrhythmia. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperthermia, or neuromuscular abnormalities. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron, several safety considerations should be observed.

- Cardiac risk assessment: monitor QT interval in patients with known cardiac disease or electrolyte abnormalities. - Electrolyte balance: correct hypokalaemia, hypomagnesaemia, or hypocalcaemia before administration. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Drug interactions: review concomitant medications that may affect cardiac conduction or serotonin levels. - Storage conditions: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics): increase risk of cardiac arrhythmia. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ondansetron effectiveness. - Apomorphine: concomitant use can cause profound hypotension.